Specific Cytokines Are Significant Biomarkers for AML
By LabMedica International staff writers Posted on 16 Oct 2019 |

Image: Myeloperoxidase positive staining from a patient with acute myeloid leukemia (Photo courtesy of Monika Nema, MD).
Acute myeloid leukemia is a hematopoietic neoplasm derived from early progenitor myeloid cells; it is characterized by clonal expansion of myeloblasts, which are immature myeloid progenitors that accumulate in the bone marrow (BM).
Immune system impairment and immunetolerance were reported in patients with acute myeloid leukemia. T cells are the most active part of the immune system, nevertheless they were found to be functionally and numerically defective in acute myeloid leukemia. Interleukin-27 (IL27) and IL35 are regulatory T cells (T-regs) related cytokines; they may be involved in eukemogenesis of acute myeloid leukemia (AML).
Scientists at Sohag University (Sohag, Egypt) recruited 70 newly diagnosed patients with primary AML and 30 matched healthy volunteers. The diagnosis of AML in the patients was made using Leishman-stained peripheral blood smears; Bone marrow (BM) aspirates or occasionally trephine biopsy; Cytochemical staining of BM specimens using myeloperoxidase (MPO), esterase and periodic acid Schiff; and immunophenotyping (IPT): monoclonal antibodies (MoAb) used for staining of blast cells were labeled with fluorescein isothiocyanate, phycoerythrin.
Serum was obtained from plain blood sample tubes that were kept at −80 °C by centrifugation. Serum levels of IL-27 and IL-35 were measured by enzyme-linked immunosorbent assay (ELISA), for both patients and controls, using the commercially available kits. Absorbance was recorded at 495 nm, IL-27 assay range was 31.25–2,000 pg/mL, and IL-35 assay range was 15.63–1,000 pg/mL. The median age of the study patients was 36 years and the range was 18–80 years. Females comprised 52.9% of the patient group.
The scientists reported that significantly higher levels of IL27 and IL35 in AML patients compared with the control subjects, with median values of 77 and 51 pg/mL compared to 37 and 22.2 pg/mL, respectively. The correlations between serum levels of IL27 and IL3 in AML patients, revealed a significant positive correlation between IL27 with, white blood cell (WBCs) count, peripheral blasts percent and myeloperoxidase (MPO) positivity. However, IL35 levels showed a significant negative correlation with platelets count and significant positive correlations with age, CD45, HLA-DR and CD34.
The authors concluded that their study demonstrated that IL27 and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique they recommended the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML. The study was published on October 1, 2019, in the Journal of Blood Medicine.
Related Links:
Sohag University
Immune system impairment and immunetolerance were reported in patients with acute myeloid leukemia. T cells are the most active part of the immune system, nevertheless they were found to be functionally and numerically defective in acute myeloid leukemia. Interleukin-27 (IL27) and IL35 are regulatory T cells (T-regs) related cytokines; they may be involved in eukemogenesis of acute myeloid leukemia (AML).
Scientists at Sohag University (Sohag, Egypt) recruited 70 newly diagnosed patients with primary AML and 30 matched healthy volunteers. The diagnosis of AML in the patients was made using Leishman-stained peripheral blood smears; Bone marrow (BM) aspirates or occasionally trephine biopsy; Cytochemical staining of BM specimens using myeloperoxidase (MPO), esterase and periodic acid Schiff; and immunophenotyping (IPT): monoclonal antibodies (MoAb) used for staining of blast cells were labeled with fluorescein isothiocyanate, phycoerythrin.
Serum was obtained from plain blood sample tubes that were kept at −80 °C by centrifugation. Serum levels of IL-27 and IL-35 were measured by enzyme-linked immunosorbent assay (ELISA), for both patients and controls, using the commercially available kits. Absorbance was recorded at 495 nm, IL-27 assay range was 31.25–2,000 pg/mL, and IL-35 assay range was 15.63–1,000 pg/mL. The median age of the study patients was 36 years and the range was 18–80 years. Females comprised 52.9% of the patient group.
The scientists reported that significantly higher levels of IL27 and IL35 in AML patients compared with the control subjects, with median values of 77 and 51 pg/mL compared to 37 and 22.2 pg/mL, respectively. The correlations between serum levels of IL27 and IL3 in AML patients, revealed a significant positive correlation between IL27 with, white blood cell (WBCs) count, peripheral blasts percent and myeloperoxidase (MPO) positivity. However, IL35 levels showed a significant negative correlation with platelets count and significant positive correlations with age, CD45, HLA-DR and CD34.
The authors concluded that their study demonstrated that IL27 and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique they recommended the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML. The study was published on October 1, 2019, in the Journal of Blood Medicine.
Related Links:
Sohag University
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more